What options are available for refractory pancreatic cancer?

Journal of the Pancreas

Volumn 13, Issue 2, 2012, Pages 163-165

  Choi, Minsig ^a   Kim, Richard ^b   Saif, Muhammad Wasif ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Drug therapy; Gemcitabine; Paclitaxel; Pancreatic neoplasms

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 84858632805     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Burris HA, III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
2. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 28, No 15_suppl (May 20 Supplement), 2010: 4010
3. T Conroy, F Desseigne and M Ychou et al., Randomized phase III trial comparing FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817.
4. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(15 Suppl):4508.
5. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B et. al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676.
6. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046-52.
7. Maeda S, Motoi F, Onogawa T, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011; 16:539.
8. Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel asweekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635-638.
9. Hosein PJ, Pastorini VH, Gomez CM, Macintyre J, Merchan JR, Ferrell A, et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine-based therapy. J Clin Oncol 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 214.
10. Ernani V, Akunyili II, Hosein PJ, Macintyre J, Rocha Lima CM. Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC). J Clin Oncol 30, 2012 (suppl 4; abstr 373)
11. Fukahori M. Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma. J Clin Oncol 30, 2012 (suppl 4; abstr 248)
12. Awasthi N, Ostapoff K, Zhang C, Schwarz MA, Schwarz R. Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer. J Clin Oncol 30, 2012 (suppl 4; abstr 170)
13. Nakamori S, Tsujie M, Miyamoto A, Kurokawa Y, Yasui M, Ikenaga M, et al. Impact of the combination of S-1 administration prior to gemcitabine as a second-line therapy for unresectable/recurrent pancreatic cancer. J Clin Oncol 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 241.